Invivyd, Inc. (IVVD)
0.6636
+0.06
(+9.18%)
USD |
NASDAQ |
Oct 15, 16:00
0.679
+0.02
(+2.32%)
After-Hours: 20:00
Invivyd Enterprise Value : 27.46M for Oct. 14, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 14, 2026 | 27.46M |
| October 13, 2026 | 38.72M |
| October 12, 2026 | 46.77M |
| October 09, 2026 | 60.89M |
| October 08, 2026 | 54.76M |
| October 07, 2026 | 63.07M |
| October 06, 2026 | 86.00M |
| October 05, 2026 | 95.67M |
| October 02, 2026 | 90.63M |
| October 01, 2026 | 88.98M |
| September 30, 2026 | 104.78M |
| September 29, 2026 | 98.88M |
| September 28, 2026 | 128.33M |
| September 25, 2026 | 123.67M |
| September 24, 2026 | 117.51M |
| September 23, 2026 | 120.40M |
| September 22, 2026 | 132.45M |
| September 21, 2026 | 148.96M |
| September 18, 2026 | 70.94M |
| September 17, 2026 | 68.26M |
| September 16, 2026 | 85.68M |
| September 15, 2026 | 92.96M |
| September 14, 2026 | 111.17M |
| September 11, 2026 | 79.84M |
| September 10, 2026 | 77.01M |
| Date | Value |
|---|---|
| September 09, 2026 | 83.32M |
| September 08, 2026 | 91.72M |
| September 04, 2026 | 91.78M |
| September 03, 2026 | 94.43M |
| September 02, 2026 | 85.29M |
| September 01, 2026 | 107.67M |
| August 31, 2026 | 129.77M |
| August 28, 2026 | 132.60M |
| August 27, 2026 | 113.62M |
| August 26, 2026 | 114.09M |
| August 25, 2026 | 125.00M |
| August 24, 2026 | 126.12M |
| August 21, 2026 | 142.03M |
| August 20, 2026 | 128.56M |
| August 19, 2026 | 131.13M |
| August 18, 2026 | 104.19M |
| August 17, 2026 | 66.58M |
| August 14, 2026 | 60.80M |
| August 13, 2026 | 50.42M |
| August 12, 2026 | 64.07M |
| August 11, 2026 | 50.96M |
| August 10, 2026 | 46.71M |
| August 07, 2026 | 66.43M |
| August 06, 2026 | 42.55M |
| August 05, 2026 | 26.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 541.66M |
| Amgen, Inc. | 273.67B |
| Anika Therapeutics, Inc. | 257.84M |
| BioCryst Pharmaceuticals, Inc. | 2.538B |
| Imunon, Inc. | 5.833M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.39M |
| Revenue (Quarterly) | 14.28M |
| Total Expenses (Quarterly) | 58.68M |
| EPS Diluted (Quarterly) | -0.1385 |
| Gross Profit Margin (Quarterly) | 86.62% |
| Profit Margin (Quarterly) | -310.8% |
| Earnings Yield | -56.21% |
| Normalized Earnings Yield | -56.21 |